Effects of Repeated Sauna Treatment on Ventricular Arrhythmias in Patients With Chronic Heart Failure

Takashi Kihara, MD; Sadatoshi Biro, MD; Yoshiyuki Ikeda, MD; Tsuyoshi Fukudome, MD; Takuro Shinsato, MD; Akinori Masuda, MD; Masaaki Miyata, MD; Shuichi Hamasaki, MD; Yutaka Otsuji, MD; Shinichi Minagoe, MD; Suminori Akiba, MD*; Chuwa Tei, MD

Background The aim of the present study was to determine whether repeated 60°C sauna treatment improves cardiac arrhythmias in chronic heart failure (CHF) patients, because ventricular arrhythmias are an important therapeutic target in CHF.

Methods and Results Thirty patients (59±3 years) with New York Heart Association functional class II or III CHF and at least 200 premature ventricular contractions (PVCs)/24 h assessed by 24-h Holter recordings were studied. They were randomized into sauna-treated (n=20) or non-treated (n=10) groups. The sauna-treated group underwent a 2-week program of a daily 60°C far infrared-ray dry sauna for 15 min, followed by 30 min bed rest with blankets, for 5 days per week. Patients in the non-treated group had bed rest in a temperature-controlled room (24°C) for 45 min. The total numbers of PVCs/24 h in the sauna-treated group decreased compared with the non-treated group [848±415 vs 3,097±1,033/24 h, p<0.01]. Heart rate variability (SDNN, standard deviation of normal-to-normal beat interval) increased [142±10 (n=16) vs 112±11 ms (n=8), p<0.05] and plasma brain natriuretic peptide concentrations decreased [229±54 vs 419±110 pg/ml, p<0.05] in the sauna-treated group compared with the non-treated group.

Conclusion Repeated sauna treatment improves ventricular arrhythmias in patients with CHF. (Circ J 2004; 68: 1146–1151)

Key Words: Heart failure; Heart rate variability; Premature ventricular contractions; Sauna

Patients with chronic heart failure (CHF) have a high prevalence of potentially serious arrhythmias and consequently, a high incidence of sudden cardiac death.1–4 The presence of ventricular arrhythmias defines a higher-risk patient group with either ischemic or non-ischemic cardiomyopathy.5–9 Antiarrhythmic medications, such as class I drugs, have been tested in myocardial infarction survivors with depressed ventricular function and in atrial fibrillation patients with a history of congestive heart failure, and most were found not to be helpful and may even increase the occurrence of arrhythmias and cardiac mortality.10–12 Some studies have shown that amiodarone improves ventricular arrhythmias and sudden cardiac death in patients with CHF, yet the improvement in total mortality remains controversial.13–15 Previous studies have demonstrated that vasodilators, such as angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, improve the prognosis and ventricular arrhythmias in patients with CHF.16–18 Therefore, arrhythmia is an important target for therapy in patients with CHF.

We have used thermal therapy with a 60°C dry sauna in many patients19–21 Furthermore, we have demonstrated that repeated sauna treatment improves the prognosis in hamsters with CHF.22 It is well recognized that alterations in the neural control of the heart, characterized by decreased vagal activity and relative sympathetic predominance, play a key role in the occurrence of cardiac arrhythmias in patients with CHF.23 Several studies have shown that reduced heart rate variability (HRV), determined from 24-h ambulatory electrocardiographic (ECG) recordings, is associated with a greater risk for ventricular fibrillation and poor prognosis in patients with CHF.24–27 Therefore, we prospectively investigated the effects of thermal therapy on cardiac arrhythmias and HRV in patients with CHF.

Methods

Study Population

We studied 30 patients with CHF, aged 28–80 years (mean age: 59±3 years): 24 patients (16 men, 8 women) had idiopathic dilated cardiomyopathy and 6 (5 men, 1 woman) had ischemic cardiomyopathy. Inclusion criteria included the presence of symptomatic CHF, left ventricular ejection fraction (LVEF) <50% by echocardiography, New York Heart Association (NYHA) functional class II–III, and >200 premature ventricular contractions (PVCs) per day on 24-h Holter monitoring. Seven patients were in NYHA functional class II, and the other 23 were in class III. They were randomized into a sauna-treated group (n=20) or a non-treated group (n=10). The mean number of PVCs/24 h was 3,123±819; the mean coronary artery ratio (CTR) on chest radiography was 58.5±1.0% (range: 49–75%); and the mean LVEF on echocardiography was 29±2% (range:
10–48%). All patients were receiving maintenance doses of medications for heart failure and arrhythmias, including angiotensin-converting enzyme inhibitors, diuretics, ß-blockers, digitalis and antiarrhythmic drugs (mexiletine), and they were in a stable clinical condition for 1 month before entering the study. They also did not have symptomatic arrhythmias. Their medications were unchanged for at least 1 month before or during this study. Written informed consent was obtained from all patients prior to participation, and the protocol was approved by the Ethics Committee of the Faculty of Medicine, Kagoshima University.

**Sauna Treatment**

Thermal therapy with a far infrared-ray 60°C dry sauna was performed as previously reported. Patients remained supine on a bed during the sauna for 15 min, followed by 30 min of bed rest with a blanket to keep them warm. Patients were weighed before and after the sauna treatment. Oral hydration with water was used to compensate for lost weight. Patients in the non-treated group remained supine on a bed during the sauna for 15 min, followed by 30 min of bed rest with a blanket to keep them warm. Patients in the non-treated group were weighed before and after the sauna treatment.

**Assessment of Clinical Symptoms**

Clinical symptoms, such as dyspnea, fatigue, sleeplessness, edema, appetite-loss and constipation, were evaluated by a self-assessment quality of life (QOL) questionnaire. Each item had 4 grades: remarkably improved, improved, no change, or worsened. Patients were classified into 3 groups based on the results of the questionnaire. Patients who answered ‘improved’ to more than 3 items were defined as the improved group, those who answered ‘worsened’ for at least 1 item were defined as the worsened group, and the others were defined as the unchanged group.

**Laboratory Examination**

A fasting blood sample was obtained in the morning to measure plasma concentrations of neurohormonal factors, including catecholamines, atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP). Plasma catecholamine (norepinephrine, epinephrine, and dopamine) concentrations were measured with high-performance liquid chromatography, and both plasma ANP and BNP concentrations were measured by radioimmunoassay. Chest radiography (CTR) and echocardiography (LVEDD, left ventricular end diastolic dimension; LAD, left atrial dimension; LVEF) also were performed.

**Ambulatory ECG Recording**

Ambulatory ECG monitoring was by 2-lead 24-h Holter monitoring (DMC-4502, Nihon Koden, Tokyo, Japan). The Holter tape recordings were analyzed on a full disclosure unit that printed out each individual QRS complex for subsequent visual examination. Complete determination of PVC frequency with a description and quantification of complex forms (multiform PVCs, couplets, and ventricular tachycardia) was undertaken by manual analysis of the full disclosure unit. For the purpose of this study, PVCs were defined as any beat of ventricular origin faster than the sinus rate, including the premature beats in couplets and ventricular tachycardia. Ventricular tachycardia was defined as ≥3 consecutive premature beats at a rate of ≥100 beats/min. There was an excellent correlation between the 2 observers with respect to determining the total number of PVCs (r=0.99), and the number of episodes of ventricular tachycardia (r=0.99). The technician and physician were unaware of the clinical information associated with the recording. Reproducibilities of the results of 24-h Holter monitoring performed twice were assessed in 13 patients with CHF: total beats, r=0.99, p<0.0001; PVCs, r=0.91, p<0.0001; couplets, r=0.95, p<0.0001; ventricular tachycardia, r=0.95, p<0.0001.

**Analysis of HRV**

Time-domain parameters of HRV were analyzed on a MARS8000 analysis system (GE Medical Systems Information Technologies, Milwaukee, WI, USA) from 2-lead 24-h Holter recordings. All tapes were manually edited for exclusion of artifacts and premature beats. A minimum of 18h of analyzable data and a minimum of 85% successive RR intervals were required for a tape to be accepted as valid. The time interval between 2 consecutive QRS complexes was calculated as the normal-to-normal (NN) interval. Abnormal QRS complexes and RR intervals
were replaced by a linear interpolation algorithm. The standard deviation (SD) of all normal beat intervals and the mean length of the NN intervals (SDNN) were used for time-domain measures from the entire recording period. We analyzed 24 patients; 6 patients with atrial fibrillation were excluded.

**Study Protocol**

Sauna treatment was performed daily for 5 days each week, for a total of 2 weeks. All examinations were performed before the first treatment and on the day after the last treatment.

**Statistical Analysis**

All data are expressed as the mean±SEM. Differences in baseline characteristics were evaluated by the chi-square test and unpaired t-test. Within-group changes between baseline and after 2 weeks were evaluated by paired t-test or Wilcoxon signed rank test for variables that were not normally distributed. Between-group comparisons were evaluated by Mann-Whitney’s U test using differences between baseline and after 2 weeks. A value of p<0.05 was considered statistically significant.

**Results**

**Baseline Clinical Characteristics and Assessment of Clinical Symptoms**

Baseline clinical characteristics are summarized in Table 1. There were no differences in age, gender, NYHA functional class, mean heart rate, blood pressure or use of drugs, such as digoxin, angiotensin-converting enzyme inhibitor, β-blockers, diuretics, nitrates, and antiarrhythmic drugs, at baseline between the 2 groups. All patients enrolled completed the study. In the sauna-treated group, no patient experienced dyspnea, angina pectoris or palpitations. Clinical symptoms related to dyspnea, fatigue, edema, appetite-loss, constipation and insomnia were improved in 17 of 20 patients and unchanged in 3 patients after the 2-week sauna treatment. However, no patients had worsening of clinical symptoms. In the non-treated group, clinical symptoms did not change after 2 weeks.

**Cardiac Arrhythmias**

At baseline, the total number of PVCs, couplets and episodes of ventricular tachycardia per day were similar between the 2 groups (Table 2). In the sauna-treated group, the total number of PVCs decreased in all patients 2 weeks after treatment. The total number of PVCs in the sauna-treated group was significantly decreased compared with the non-treated group after 2 weeks (p<0.01, Table 2). The total number of couplets and episodes of ventricular tachycardia per day also decreased significantly in the sauna-treated group compared with the non-treated group (Table 2). The prevalence of couplets and ventricular tachycardia in the sauna-treated group compared with the non-treated group was 45% vs 90%, p<0.05, and 20% vs 80%, p<0.01, respectively. The total number of PACs did not significantly change between the 2 groups after 2 weeks (170±102 vs 617±375, p=0.07).

**HRV**

There was no difference in SDNN at the baseline between the 2 groups, but after 2 weeks, SDNN was sig-

---

**Table 2** Frequency of Ventricular Arrhythmias and Heart Rate Variability at Baseline and After 2 Weeks in the 2 Groups

<table>
<thead>
<tr>
<th></th>
<th>Sauna-treated group</th>
<th>Non-treated group</th>
<th>Comparison with both groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After 2 weeks</td>
<td>Baseline</td>
</tr>
<tr>
<td>PVCs/24h (beats/24h)</td>
<td>3,161±104</td>
<td>848±415**</td>
<td>3,048±914</td>
</tr>
<tr>
<td>Couplets (episodes/24h)</td>
<td>71±5</td>
<td>15±11**</td>
<td>69±45</td>
</tr>
<tr>
<td>VT (episodes/24h)</td>
<td>20±9</td>
<td>45±3**</td>
<td>21±8</td>
</tr>
<tr>
<td>Mean RR interval (ms)</td>
<td>807±28</td>
<td>831±42</td>
<td>858±63</td>
</tr>
<tr>
<td>SDNN (ms)</td>
<td>113±8</td>
<td>142±10**</td>
<td>111±10</td>
</tr>
</tbody>
</table>

PVCs, premature ventricular contractions; VT, ventricular tachycardia; SDNN, standard deviation of NN interval; NS, not significant. All values are given as the mean±SE. **p<0.01 vs baseline.

**Table 3** Various Parameters at Baseline and After 2 Weeks in the 2 Groups

<table>
<thead>
<tr>
<th></th>
<th>Sauna-treated group</th>
<th>Non-treated group</th>
<th>Comparison with both groups</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
<td>After 2 weeks</td>
<td>Baseline</td>
</tr>
<tr>
<td>NYHA (I/II/III)</td>
<td>0/5/15</td>
<td>0/15/5**</td>
<td>0/2/8</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>57±3</td>
<td>56±3</td>
<td>53±3</td>
</tr>
<tr>
<td>SBP (mmHg)</td>
<td>107±4</td>
<td>100±3</td>
<td>108±5</td>
</tr>
<tr>
<td>DBP (mmHg)</td>
<td>65±3</td>
<td>62±2</td>
<td>67±3</td>
</tr>
<tr>
<td>CTR (%)</td>
<td>59±1</td>
<td>56±2**</td>
<td>58±1</td>
</tr>
<tr>
<td>LVEDD (mm)</td>
<td>64±2</td>
<td>61±2*</td>
<td>64±3</td>
</tr>
<tr>
<td>LAD (mm)</td>
<td>46±2</td>
<td>44±2</td>
<td>47±2</td>
</tr>
<tr>
<td>LVEF (%)</td>
<td>29±2</td>
<td>32±2*</td>
<td>29±3</td>
</tr>
<tr>
<td>NE (pg/ml)</td>
<td>431±56</td>
<td>413±76</td>
<td>414±42</td>
</tr>
<tr>
<td>EP (pg/ml)</td>
<td>23±4</td>
<td>25±3±4</td>
<td>24±64</td>
</tr>
<tr>
<td>DOPA (pg/ml)</td>
<td>13±2±3</td>
<td>13±2±3</td>
<td>14±2±4</td>
</tr>
<tr>
<td>ANP (pg/ml)</td>
<td>121±23</td>
<td>81±19**</td>
<td>126±32</td>
</tr>
<tr>
<td>BNP (pg/ml)</td>
<td>425±102</td>
<td>229±54**</td>
<td>415±98</td>
</tr>
</tbody>
</table>

NYHA, New York Heart Association; SBP, systolic blood pressure; DBP, diastolic blood pressure; CTR, cardiothoracic ratio; LVEDD, left ventricular end diastolic dimension; LAD, left atrial dimension; LVEF, left ventricular ejection fraction; NE, norepinephrine; EP, epinephrine; DOPA, dopamine; ANP, atrial natriuretic peptide; BNP, brain natriuretic peptide; NS, not significant. All values are given as the mean±SE. *p<0.05 vs baseline. **p<0.01 vs baseline.
significantly greater in the sauna-treated group compared with the non-treated group (Table 2).

**Neuro-Hormonal Factors**

At baseline, there were no differences in the plasma concentrations of ANP, BNP, or catecholamine between the 2 groups. After 2 weeks, there were no differences in the plasma concentrations of ANP or catecholamine between the 2 groups, but the plasma concentration of BNP in the sauna-treated group was significantly lower than in the non-treated group (229±54 pg/ml vs 419±110 pg/ml, p<0.05; Table 3).

**NYHA Functional Class, Chest Radiography, Echocardiography and Laboratory Parameters**

At baseline, there were no differences in NYHA functional class, CTR or LVEDD between the 2 groups, but after 2 weeks, there was a significant difference in NYHA functional class, body weight, and CTR in the sauna-treated group; LVEDD did not change between the 2 groups. Laboratory parameters, including liver function tests (aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, Ý-glutamyl transpeptidase etc), creatinine, electrolytes (Na, Cl, K) and hematocrit, did not change after 2 weeks in either group (data not shown).

**Discussion**

In the present study, we found that repeated 60°C sauna treatment improved ventricular arrhythmias. Furthermore, we observed that thermal therapy increased HRV and reduced the plasma concentration of BNP in patients with CHF.

The incidence of ventricular arrhythmias is extremely high in patients with CHF: approximately 80% or more of CHF patients have frequent ventricular premature beats and approximately 50% of them have runs of nonsustained ventricular tachycardia.1-3 Sudden death because of ventricular arrhythmias accounts for approximately half of all deaths in patients with CHF.4-6 Several studies have shown an association between ventricular arrhythmias and mortality in patients with CHF.7-9 Mortality in patients with CHF, the ventricular wall is chronically stretched as well as ventricular arrhythmias, in patients with CHF are improved by treatment with non-antiarrhythmic drugs, such as angiotensin-converting enzyme inhibitors10-13 and spironolactone.14 Our present results demonstrated that thermal therapy reduced the total number of PVCs, coupled, and episodes of ventricular tachycardia in patients with CHF and we have already shown that thermal therapy reduced mortality in hamsters with CHF.15 We suggest that improvement of ventricular arrhythmias may be one of the mechanisms by which repeated thermal therapy improves the prognosis in patients with CHF.

Although the mechanisms of ventricular arrhythmias occurring in patients with CHF are still unclear, experimental evidence suggests that the development of delayed and early afterdepolarization-induced triggered activity and automaticity, in addition to conditions favoring reentry, are related to arrhythmias in the setting of heart failure. Modulating factors, such as sympathetic activation, electrolyte disturbances and chronic left ventricular stretch, are also present in the setting of heart failure.16-18 It is well-established that the sympathetic nervous system is activated in patients with CHF,19-21 and analysis of HRV provides important information about sympathetic nervous activity in these patients.22,23 Data from the recent United Kingdom-Heart failure Evaluation and Assessment of Risk Trial (UK-HEART) suggest that reduced HRV, analyzed by a traditional time-domain method (including SDNN), is related to the risk of ventricular arrhythmias and sudden death in patients with CHF.24-26 We and so far none of the in-hospital patients has shown any concern with mortality.14 Previous studies have demonstrated that thermal therapy reduced mortality in hamsters with CHF.27 We suggest that improvement of ventricular arrhythmias may be one of the mechanisms by which repeated thermal therapy improves the prognosis in patients with CHF.

The chronic stretch of cardiac myocytes contributes to shortening of the action potential duration and mild decreases in the action potential amplitude and resting membrane potential.28 These changes may be arrhythmogenic by decreasing reentry and abnormal automaticity.29 In patients with CHF, the ventricular wall is chronically stretched because of increases in ventricular volume and/or pressure overload. It is well-established that BNP is secreted predominantly by the ventricle in response to ventricular wall stretch.30 On the basis of our findings, including previous data31 which showed significantly decreased plasma concentrations of BNP after 2 weeks of sauna treatment, we speculate that another mechanism responsible for decreased ventricular arrhythmias may be reduction of ventricular wall stretch.

Electrolyte disturbances, such as hypokalemia and hypomagnesemia, are prevalent in patients treated with diuretics and are implicated as a cause of ventricular arrhythmias associated with CHF. However, we did not observe significant change in the electrolyte concentrations after 2 weeks (data not shown).

We have treated many CHF patients with sauna therapy and so far none of the in-hospital patients has shown any deterioration in their condition. However, thermal therapy does not appear to be indicated for CHF patients with aortic stenosis or obstructive hypertrophic cardiomyopathy because the pressure gradient is increased. In the present study, only CHF patients with NYHA functional class II or III underwent sauna treatment. It is well-known that the more severe the CHF, the more prevalent are ventricular arrhythmias. We evaluated the effects of sauna therapy on

**Circulation Journal**  Vol.68, December 2004
ventricular arrhythmias at 2 weeks, but further studies of the long-term effects and benefit in CHF patients with NYHA functional class IV are needed.

In conclusion, repeated 60°C sauna treatment decreased ventricular arrhythmias in CHF patients with NYHA functional class II or III.

Acknowledgment
This study was supported in part by a Grant-in-Aid from the Japan Heart Foundation/Pfizer Grant for Cardiovascular Disease Research.

References


